David Amsellem
Stock Analyst at Piper Sandler
(4.85)
# 382
Out of 4,531 analysts
902
Total ratings
61%
Success rate
14.8%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterated: Buy | $298 | $254.49 | +17.10% | 24 | Jul 17, 2026 | |
| BIIB Biogen | Reiterated: Buy | $225 | $205.99 | +9.23% | 30 | Jul 15, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $258 | $230.00 | +12.17% | 26 | Jul 14, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterated: Buy | $42 | $32.03 | +31.13% | 68 | Jul 8, 2026 | |
| AMGN Amgen | Reiterated: Buy | $427 | $366.29 | +16.57% | 49 | Jun 29, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $43 | $52.72 | -18.44% | 40 | Jun 22, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $301 | $247.53 | +21.60% | 67 | Jun 16, 2026 | |
| VTRS Viatris | Maintained: Hold | $12 | $17.29 | -30.60% | 24 | Jun 4, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Buy | $66 | $48.04 | +37.39% | 69 | Jun 4, 2026 | |
| AMRX Amneal Pharmaceuticals | Maintained: Buy | $17 | $17.85 | -4.76% | 41 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $60.74 | +23.48% | 17 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $90.52 | -2.78% | 31 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 → $59 | $40.54 | +45.54% | 14 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $10.50 | +71.43% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $4.12 | +94.17% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $25 → $21 | $19.75 | +6.36% | 40 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 → $48 | $44.29 | +8.38% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $179 → $207 | $170.88 | +21.14% | 42 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $5 → $14 | $13.52 | +3.55% | 18 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $94 → $111 | $79.20 | +40.15% | 4 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $44 | $36.08 | +21.95% | 45 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $46 | $33.77 | +36.22% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $26.99 | +77.84% | 3 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 → $8 | $8.80 | -9.09% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $9 | $9.60 | n/a | 19 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 → $12 | $25.61 | n/a | 39 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $4.21 | $6.78 | n/a | 64 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $18 | $3.86 | n/a | 9 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $12 | $3.20 | n/a | 12 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $26 → $17 | $0.595 | n/a | 29 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 | $0.0077 | n/a | 7 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $3 | $0.761 | n/a | 5 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $175 | $0.000001 | n/a | 7 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $25.05 | n/a | 1 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2 | $1.33 | n/a | 10 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $0.01316 | n/a | 1 | Nov 11, 2013 |
AbbVie
Jul 17, 2026
Reiterated: Buy
Price Target: $298
Current: $254.49
Upside: +17.10%
Biogen
Jul 15, 2026
Reiterated: Buy
Price Target: $225
Current: $205.99
Upside: +9.23%
Axsome Therapeutics
Jul 14, 2026
Reiterated: Buy
Price Target: $258
Current: $230.00
Upside: +12.17%
Teva Pharmaceutical Industries
Jul 8, 2026
Reiterated: Buy
Price Target: $42
Current: $32.03
Upside: +31.13%
Amgen
Jun 29, 2026
Reiterated: Buy
Price Target: $427
Current: $366.29
Upside: +16.57%
Alkermes
Jun 22, 2026
Reiterated: Buy
Price Target: $43
Current: $52.72
Upside: -18.44%
Jazz Pharmaceuticals
Jun 16, 2026
Reiterated: Buy
Price Target: $301
Current: $247.53
Upside: +21.60%
Viatris
Jun 4, 2026
Maintained: Hold
Price Target: $12
Current: $17.29
Upside: -30.60%
Supernus Pharmaceuticals
Jun 4, 2026
Maintained: Buy
Price Target: $66
Current: $48.04
Upside: +37.39%
Amneal Pharmaceuticals
Jun 4, 2026
Maintained: Buy
Price Target: $17
Current: $17.85
Upside: -4.76%
Jun 3, 2026
Reiterated: Buy
Price Target: $75
Current: $60.74
Upside: +23.48%
Jun 1, 2026
Reiterated: Buy
Price Target: $88
Current: $90.52
Upside: -2.78%
May 22, 2026
Reiterated: Buy
Price Target: $54 → $59
Current: $40.54
Upside: +45.54%
May 15, 2026
Reiterated: Buy
Price Target: $18
Current: $10.50
Upside: +71.43%
May 15, 2026
Reiterated: Buy
Price Target: $8
Current: $4.12
Upside: +94.17%
May 11, 2026
Maintained: Hold
Price Target: $25 → $21
Current: $19.75
Upside: +6.36%
May 8, 2026
Reiterated: Buy
Price Target: $49 → $48
Current: $44.29
Upside: +8.38%
May 6, 2026
Reiterated: Buy
Price Target: $179 → $207
Current: $170.88
Upside: +21.14%
Apr 28, 2026
Upgraded: Hold
Price Target: $5 → $14
Current: $13.52
Upside: +3.55%
Apr 23, 2026
Maintained: Buy
Price Target: $94 → $111
Current: $79.20
Upside: +40.15%
Apr 23, 2026
Maintained: Hold
Price Target: $44
Current: $36.08
Upside: +21.95%
Apr 22, 2026
Reiterated: Buy
Price Target: $48 → $46
Current: $33.77
Upside: +36.22%
Apr 20, 2026
Reiterated: Buy
Price Target: $48
Current: $26.99
Upside: +77.84%
Nov 7, 2025
Maintained: Hold
Price Target: $4 → $8
Current: $8.80
Upside: -9.09%
Mar 21, 2025
Downgraded: Hold
Price Target: $15 → $9
Current: $9.60
Upside: n/a
Nov 7, 2024
Reiterated: Hold
Price Target: $11 → $12
Current: $25.61
Upside: n/a
Oct 31, 2024
Reiterated: Sell
Price Target: $4.21
Current: $6.78
Upside: n/a
May 22, 2024
Reiterated: Buy
Price Target: $21 → $18
Current: $3.86
Upside: n/a
May 14, 2024
Reiterated: Hold
Price Target: $1 → $12
Current: $3.20
Upside: n/a
Aug 9, 2023
Downgraded: Sell
Price Target: $26 → $17
Current: $0.595
Upside: n/a
May 25, 2022
Maintained: Buy
Price Target: $2
Current: $0.0077
Upside: n/a
Nov 10, 2021
Reiterated: Buy
Price Target: $20 → $3
Current: $0.761
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $175
Current: $0.000001
Upside: n/a
Jan 23, 2019
Upgraded: Hold
Price Target: n/a
Current: $25.05
Upside: n/a
Oct 12, 2017
Reiterated: Hold
Price Target: $3 → $2
Current: $1.33
Upside: n/a
Nov 11, 2013
Initiated Coverage: Buy
Price Target: $6
Current: $0.01316
Upside: n/a